Clinical Trial

A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, multi-cohort, multi-center clinical trial targeting patients with intermediate-to-high-risk rhabdomyosarcoma who have not previously received systemic anti-tumor treatment. It aims to evaluate the efficacy and safety of all-trans retinoic acid combined with VAC chemotherapy.
Trial Details
NCT Number NCT07355855
Lead Sponsor Fudan University
Conditions Rhabdomyosarcoma
Enrollment 106 participants
Start Date 2026-01
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-21